ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v10i5.822ppharm-174Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESВЛИЯНИЕ ПОЛИМОРФИЗМА С3435Т ГЕНА MDR1 НА ЭФФЕКТИВНОСТЬ ТЕРАПИИ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТАINFLUENCE OF C3435T POLYMORPHISM OF THE GENE MDR1 ON THE EFFICACY OF JUVENILE IDIOPATHIC ARTHRITIS THERAPYРохлинаФ. В.RokhlinaF. V.

ассистент кафедры педиатрии им. проф. И.М. Воронцова ФП и ДПО СПбГПМУ

assistant of the Vorontsov pediatrics department of the postgraduate and additional professional education faculty at the SPbSPMU

faina.rokhlina@gmail.comНовикГ. А.NovikG. A.КалининаН. М.KalininaN. M.БычковаН. В.BychkovaN. V.ФилипповаЮ. Н.FilippovaY. N.ЗарайскийМ. И.ZarayskiyM. I.Санкт-Петербургский государственный педиатрический медицинский университет Минздрава РоссииРоссияSaint Petersburg State Pediatric Medical University of the Ministry of Health of RussiaRussian FederationСанкт-Петербургский государственный педиатрический медицинский университет Минздрава России, Российская ФедерацияРоссияSaint Petersburg State Pediatric Medical University of the Ministry of Health of Russia, Russian FederationRussian FederationВсероссийский центр экстренной и радиационной медицины им. А.М. Никифорова МЧС России, Санкт-Петербург, Российская ФедерацияРоссияNikiforov All-Russian Center of Emergency and Radiation Medicine of the Ministry of Emergency Situations of Russia, Saint Petersburg, Russian FederationRussian FederationСанкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Российская ФедерацияРоссияPavlov Saint Petersburg State Medical University, Russian FederationRussian Federation201301102013105Педиатрическая фармакология4651Copyright © Рохлина Ф.В., Новик Г.А., Калинина Н.М., Бычкова Н.В., Филиппова Ю.Н., Зарайский М.И., 20132013Рохлина Ф.В., Новик Г.А., Калинина Н.М., Бычкова Н.В., Филиппова Ю.Н., Зарайский М.И.Rokhlina F.V., Novik G.A., Kalinina N.M., Bychkova N.V., Filippova Y.N., Zarayskiy M.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/174

Juvenile idiopathic arthritis (JIA) is a multifactorial disease: its pathogenesis includes immunological and genetic factors. Gene MDR1 is responsible for resistance to various cytotoxic drugs. Product of gene MDR1 - P-glycoprotein (P-gp) acts as a transmembrane pump, thus affecting action of drugs. The research objective was to determine connection of C3435T polymorphism of gene MDR1 with P-protein’s expression level in children with JIA. P-protein was revealed in all the patents involved in our trial: the protein was revealed on peripheral blood lymphocytes before and after stimulation of interleukin 2. The authors also picked out genome DNA using phenol-chloroform extraction and detected C3435T polymorphism of the gene MDR1 using polymerase chain reaction. Methotrexate concentration in blood serum was determined using a standard method of fluorescent polarization (FPIA) using the Abbott apparatus TDxFLx. Statistical manipulation of the data obtained in the course of the trial was conducted using software Statistica 6.0. C3435T polymorphism of gene MDR1 affects therapy efficacy. Determination of both basal and stimulated (in vitro) P-glycoprotein may be used as additional criterion in the evaluation of disease activity.

ювенильный идиопатический артритР-гликопротеинген множественной лекарственной устойчивостиполиморфизм С3435Тjuvenile idiopathic arthritisP-glycoproteinmultidrug resistance genC3435T polymorphismReferencesHarris J. G., Kessler E. A., Verbsky J. W. Update on the Treatment of Juvenile Idiopathic Arthritis. Curr Allergy Asthma Rep. 2013; 13: 337–346.Harris J. G., Kessler E. A., Verbsky J. W. Update on the Treatment of Juvenile Idiopathic Arthritis. Curr. Allergy Asthma Rep. 2013; 13: 337–346.Bulatovic M., Heijstek M. W., Verkaaik M. et al. High Prevalence of Methotrexate Intolerance in Juvenile Idiopathic Arthritis. Art Rheumat. 2011; 63 (7): 2007–2013.Bulatovic M., Heijstek M. W., Verkaaik M. et al. High Prevalence of Methotrexate Intolerance in Juvenile Idiopathic Arthritis. Art Rheumat. 2011; 63 (7): 2007–2013.Chin J. E., Soffir R., Noonan K. E. et al. Structure and Expression of the Human MDR (P-Glycoprotein) Gene Family. Molecular and cellular biology. 1989. Р. 3808–3820.Chin J. E., Soffir R., Noonan K. E. et al. Structure and Expression of the Human MDR (P-Glycoprotein) Gene Family. Molecular and cellular biology. 1989. Р. 3808–3820.Миронова Ж. А., Трофимов В. И., Симакова М. А. и др. Генмножественной лекарственной устойчивости (MDR1) — маркер терапевтической резистентности и степени тяжести заболеваний. Российский аллергологический журнал. 2010; 3: 9–13.Mironova Zh. A., Trofimov V. I., Simakova M. A. et al. Rossiiskii allergologicheskii zhurnal = Russian allergological journal. 2010; 3: 9–13.Annese V., Valvano M. R., Palmieri O. et al. World Multidrug resistance 1 gene in inflammatory bowel disease: A Meta-analysis. J Gastroenterol. 2006 June 21; 12 (23): 3636–3644.Annese V., Valvano M. R., Palmieri O. et al. World Multidrug resistance 1 gene in inflammatory bowel disease: A Meta-analysis. J. Gastroenterol. 2006 June 21; 12 (23): 3636–3644.Ambudkar S. V., Kimchi-Sarfaty C., Sauna Z. E. et al. P-glycoprotein: from genomics to mechanism. Oncogene. 2003; 22: 7468–7485.Ambudkar S. V., Kimchi-Sarfaty C., Sauna Z. E. et al. P-glycoprotein: from genomics to mechanism. Oncogene. 2003; 22: 7468–7485.Cantarini L., Simonini G., Frediani B. et al. Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert Opin Investig Drugs. 2012; 21 (1).Cantarini L., Simonini G., Frediani B. et al. Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert. Opin. Investig Drugs. 2012; 21 (1).Sauna Z. E., Kim I.-W., Ambudkar S.V.J Genomics and the mechanism of P-glycoprotein (ABCB1). Bioenerg Biomembr. 2007; 39: 481–487.Sauna Z. E., Kim I.-W., Ambudkar S.V.J Genomics and the mechanism of P-glycoprotein (ABCB1). Bioenerg Biomembr. 2007; 39: 481–487.Pawlik A., Wrzesniewska J., Fiedorowicz-Fabrycy I. et al. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2004 Sep; 42 (9): 496–503.Pawlik A., Wrzesniewska J., Fiedorowicz-Fabrycy I. et al. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol Ther. 2004 Sep; 42 (9): 496–503.Chen J., Chen L., Mao N. et al. Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population. Rheumatol Int. 2011.Chen J., Chen L., Mao N. et al. Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population. Rheumatol. Int. 2011.Cizmarikova M., Wagnerova M., Schonova L. et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. The Pharmacogenomics Journal. 2010; 10: 62–69.Cizmarikova M., Wagnerova M., Schonova L. et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. The Pharmacogenomics Journal. 2010; 10: 62–69.Sills G. J., Mohanraj R., Butler E. et al. Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment. Epilepsia. 2005; 46 (5): 643–647.Sills G. J., Mohanraj R., Butler E. et al. Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment. Epilepsia. 2005; 46 (5): 643–647.Kato T., Hamada A., Mori S. et al. Genetic Polymorphisms in Metabolicand Cellular Transport Pathway of Methotrexate Impact Clinical Outcome of Methotrexate Monotherapy in Japanese patients with Rheumatoid Arthritis. Drug Metab Pharmacokinet. 2012; 27 (2): 192–199.Kato T., Hamada A., Mori S. et al. Genetic Polymorphisms in Metabolicand Cellular Transport Pathway of Methotrexate Impact Clinical Outcome of Methotrexate Monotherapy in Japanese patients with Rheumatoid Arthritis. Drug. Metab. Pharmacokinet. 2012; 27 (2): 192–199.Jaap F., Stucki G., Piet L. C. M. van Riel. Rheumatoid Arthritis Measures Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis & Rheumatism (Arthritis Care & Research). 2003 Oct. 15; 49 (5): S214–S224. Doi 10.1002/art.11407 © 2003, American College of Rheumatology.Jaap F., Stucki G., Piet L. C. M. van Riel. Rheumatoid Arthritis Measures Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis & Rheumatism (Arthritis Care & Research). 2003 Oct. 15; 49 (5): S214–S224. Doi 10.1002/art.11407 © 2003, American College of Rheumatology.Wallace C. A. Current management of juvenile idiopathic arthritis. Best Practice & Research Clinical Rheumatology. 2006. Р. 279–300.Wallace C. A. Current management of juvenile idiopathic arthritis. Best Practice & Research Clinical Rheumatology. 2006. Р. 279–300.Foeldvari I., Wierk A. Effectiveness of Leflunomide in Patients with Juvenile Idiopathic Arthritis in Clinical Practice. J Rheumatol. 2010. Р. 1763–1767.Foeldvari I., Wierk A. Effectiveness of Leflunomide in Patients with Juvenile Idiopathic Arthritis in Clinical Practice. J. Rheumatol. 2010. pp. 1763–1767.Кетлинский С. А., Симбирцев А. С. Цитокины. СПб.: ООО «Издательство Фолиант». 2008. С. 267–278.Ketlinskii S. A., Simbirtsev A. S. Tsitokiny [Cytokines]. St. Petersburg, «Izdatel'stvo Foliant» LLC, 2008. pp. 267–278.

The authors declare that there are no conflicts of interest present.